Ribavarin: Difference between revisions
ClaireLewis (talk | contribs) (Created page with "==Administration== *Type: *Dosage Forms: *Routes of Administration: *Common Trade Names: ==Adult Dosing== ==Pediatric Dosing== ==Special Populations== *Drug Ratings in...") |
ClaireLewis (talk | contribs) No edit summary |
||
| Line 1: | Line 1: | ||
==Administration== | ==Administration== | ||
*Type: | *Type: Antiviral- FDA approved for Hepatitis C, severe RSV infection. Off-label use: herpes simplex, influenza, viral hemorrhagic fever | ||
*Dosage Forms: | *Dosage Forms: | ||
*Routes of Administration: | *Routes of Administration: Oral, inhalation | ||
*Common Trade Names: | *Common Trade Names: | ||
==Adult Dosing== | ==Adult Dosing== | ||
*200-1000mg daily (dose depends on genotype and concurrent treatment with interferon) | |||
==Pediatric Dosing== | ==Pediatric Dosing== | ||
*Hep C: >2 years old: 15mg/kg daily OR 400-1200mg daily | |||
*RSV (severe cases): 20mg/ml aerosolized over 12-18 hours x 3-7 days | |||
==Special Populations== | ==Special Populations== | ||
*[[Drug Ratings in Pregnancy|Pregnancy Rating]]: | *[[Drug Ratings in Pregnancy|Pregnancy Rating]]: X | ||
*[[Lactation risk categories|Lactation risk]]: | *[[Lactation risk categories|Lactation risk]]: Infant risk cannot be ruled out | ||
*Renal dosing: reduced doses for mild-moderate impairment, do not use if CrCl <50 | |||
==Contraindications== | ==Contraindications== | ||
*Allergy to class/drug | *Allergy to class/drug | ||
*Autoimmune hepatitis | |||
*Coadministration with didanosine | |||
*Hemoglobinopathy (e.g. thalassemia, sickle cell) | |||
*Pregnant or potentially pregnant women, men who may impregnate someone | |||
*Renal impairment (CrCl <50) | |||
==Adverse Reactions== | ==Adverse Reactions== | ||
===Serious=== | ===Serious=== | ||
*Hemolytic anemia, TTP | |||
*Bacterial disease | |||
*Hepatotoxicity | |||
*MI | |||
*Suicide | |||
===Common=== | ===Common=== | ||
*Neutropenia | |||
*Nausea, vomiting, diarrhea | |||
*Asthenia, dizziness, fatigue | |||
*Weight loss | |||
*Pruritus | |||
==Pharmacology== | ==Pharmacology== | ||
*Half-life: | *Half-life: ~300 hours | ||
*Metabolism: | *Metabolism: | ||
*Excretion: | *Excretion: Mostly renal | ||
==Mechanism of Action== | ==Mechanism of Action== | ||
*Mechanism not well understood | |||
==Comments== | ==Comments== | ||
==See Also== | ==See Also== | ||
*[[Viral hepatitis]] | |||
==References== | ==References== | ||
<references/> | <references/> | ||
[[Category:Pharmacology]] | [[Category:Pharmacology]] | ||
Revision as of 03:35, 12 September 2016
Administration
- Type: Antiviral- FDA approved for Hepatitis C, severe RSV infection. Off-label use: herpes simplex, influenza, viral hemorrhagic fever
- Dosage Forms:
- Routes of Administration: Oral, inhalation
- Common Trade Names:
Adult Dosing
- 200-1000mg daily (dose depends on genotype and concurrent treatment with interferon)
Pediatric Dosing
- Hep C: >2 years old: 15mg/kg daily OR 400-1200mg daily
- RSV (severe cases): 20mg/ml aerosolized over 12-18 hours x 3-7 days
Special Populations
- Pregnancy Rating: X
- Lactation risk: Infant risk cannot be ruled out
- Renal dosing: reduced doses for mild-moderate impairment, do not use if CrCl <50
Contraindications
- Allergy to class/drug
- Autoimmune hepatitis
- Coadministration with didanosine
- Hemoglobinopathy (e.g. thalassemia, sickle cell)
- Pregnant or potentially pregnant women, men who may impregnate someone
- Renal impairment (CrCl <50)
Adverse Reactions
Serious
- Hemolytic anemia, TTP
- Bacterial disease
- Hepatotoxicity
- MI
- Suicide
Common
- Neutropenia
- Nausea, vomiting, diarrhea
- Asthenia, dizziness, fatigue
- Weight loss
- Pruritus
Pharmacology
- Half-life: ~300 hours
- Metabolism:
- Excretion: Mostly renal
Mechanism of Action
- Mechanism not well understood